Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 17 of 33 · 1561 articles
Researchers present a small platelet-related gene signature (TRIM22, TIMP1, RAC2) that may help understand UC biology and point toward blood-based biomarkers. If validated further, such markers might aid noninvasive...
Biomarker discordance is common in treat-to-target IBD care; understanding which tests reflect local gut inflammation versus systemic response can help avoid unnecessary treatment changes and guide targeted...
CDI is a serious infection that raises the risk of death for people with IBD. This study shows mortality linked to IBD+CDI changed over the last 25 years and that racial, geographic, and urban–rural disparities...
If you or a patient is about to start infliximab for ulcerative colitis, routine blood counts may help identify those unlikely to respond to induction therapy; a high negative predictive value suggests these markers...
This study suggests a new, compact DNA-methylation biomarker that identifies accelerated aging in the colon linked to chronic inflammation (IBD) and pre-cancerous conditions. Such biomarkers could eventually help...
The study shows that mucosal CD3+ T‑cell density is higher in dogs with an IBD-like condition than in healthy dogs, suggesting mucosal T‑cell infiltration is part of the disease but may not reflect how sick an individual...
The study suggests a traditional Chinese medicine formula can reduce disease signs in a mouse model of chronic relapsing ulcerative colitis and that its effects are mediated by changes in the gut microbiota and microbial...
A validated claims-based algorithm could enable larger, more efficient studies of fibrostenosis in Crohn’s disease using real-world data — helping researchers and clinicians better measure how often stricturing...
Researchers are exploring ways to prioritize who needs colonoscopy sooner; adding TCM features to prediction models might change triage performance. Patients and clinicians interested in pre-endoscopic risk tools or...
This trial tests a non-drug way (virtual reality medical-hypnosis content) to reduce pain and embarrassment during rectosigmoidoscopy — a common, sometimes poorly tolerated procedure in ulcerative colitis that patients...
A dietary multi-mineral supplement is being tested in a Phase 2 trial to see if it can improve symptoms, influence inflammation biomarkers, and help induce or maintain remission in people with ulcerative colitis.
This analysis suggests enteral nutrition may be more effective than a low-residue diet for clinical response in adults with ulcerative colitis and that some dietary strategies may raise albumin, but the underlying trial...
Basal crypt dysplasia is easy to miss but linked to higher risk of advanced colorectal neoplasia in longstanding IBD. Improved recognition and use of p53 immunohistochemistry or complementary biomarkers could affect...
NUDT15 genotyping can identify people at high risk of severe thiopurine-induced myelosuppression; if cost-effective, testing could change how clinicians choose or dose thiopurines for IBD, potentially preventing serious...
Cure8 found this source from Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, but the page could not be read reliably yet....
This method helps translate complex paired microbiome and metabolome data into coherent functional modules; that could clarify microbial metabolic alterations in IBD or IBS and guide future biomarker or mechanistic...
The study suggests a dietary/prebiotic compound (2'-FL) can change gut microbes and patient-reported disease control in mild-to-moderate UC, which could point to non-drug ways to support symptoms and microbiome health.
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK,...
Intestinal ultrasound provides a noninvasive, real-time way to see bowel inflammation and may reveal treatment response earlier than symptoms alone. That can help clinicians make timely treatment changes to prevent...
These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...
Surveillance colonoscopies in IBD are meant to detect dysplasia or cancer; this report shows some solitary polyps may be benign retention polyps. Correct endoscopic removal and pathology spare patients from unnecessary...
Vitamin D deficiency was common among Albanian patients with IBD and showed a weak inverse association with disease activity in ulcerative colitis, suggesting vitamin D status may relate to symptom burden or...
Distinguishing Crohn’s disease from intestinal tuberculosis can change treatment (immune suppression versus anti‑tubercular therapy) and outcomes. This review summarizes which findings have tended to favor one diagnosis...
This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.
This study will collect real-world data on etrasimod, an oral S1P receptor modulator, in people with ulcerative colitis, using patient-reported symptom measures over one year — information that may help patients and...
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
A rapid stool molecular test could offer a noninvasive way to measure inflammation, predict relapse, and monitor treatment response in children with IBD—areas where current tests have limitations.
Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
The study points to three bile-acid–related genes that may be linked to inflammation in ulcerative colitis and could serve as biomarkers or targets for future research into disease mechanisms and patient stratification.
Treg/Th17 balance is a central immune mechanism implicated in IBD pathogenesis; understanding how microbes, metabolites, and tissue context control that balance could inform new biomarkers and targeted therapies.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and CRP. The original article is from Alimentary Pharmacology & Therapeutics.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Crohn's disease, and Inflammatory bowel disease. The original article is from Alimentary Pharmacology &...
The project aims to enable simultaneous RNA-level profiling of microbes and host cells from human biopsies, which could reveal early microbial and host gene-expression patterns linked to subclinical Crohn’s disease and...
Adding a mesalazine retention enema to oral mesalazine improved short-term symptom relief and endoscopic signs of mucosal healing in mild-to-moderate left-sided ulcerative colitis in this retrospective study. That could...
CT-detected terminal ileitis was due to Crohn’s disease in only a small minority (12.5%) of cases in this cohort, so most patients with this imaging finding will need further testing to determine the cause.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
If you have moderate–severe ulcerative colitis, this study suggests that typical phase III trials may exclude more than half of patients seen in specialty clinics, which can make trial results less representative of...
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
The study links NAD+ precursor (NMN) supplementation to changes in TGF-β–associated gene programs, intestinal immune signatures, and the gut microbiome in mouse colitis models — pathways relevant to fibrosis and...
IBD-U means no clear Crohn’s or ulcerative colitis diagnosis yet — that uncertainty can affect treatment decisions and follow-up. The review highlights tests that may help clarify diagnosis and stresses that many...
Pharmacokinetics affect how well biologic drugs work for IBD. Better PK data could help explain why many patients have inadequate responses and could inform personalized dosing for IL-23p19 inhibitors used in Crohn’s...
This paper explores whether polygenic risk scores (PRS) predict key long-term outcomes after IBD diagnosis — notably intestinal surgery — which could be relevant for risk stratification research and future clinical tools...
Capsule endoscopy can safely help diagnose small-bowel disease in very young children, including cases of suspected IBD, and may be particularly helpful when blood tests or imaging suggest inflammation or low albumin....
Noninvasive intestinal ultrasound with superb microvascular imaging (SMI) may help predict the presence and size of endoscopic ulcers in the terminal ileum of people with Crohn’s disease. That could improve noninvasive...
Unexplained mid‑esophageal ulcers with recurrent oral ulcers can reflect rare systemic inflammatory diseases such as gastrointestinal Behçet disease, and they often need broad testing to exclude infections, malignancy,...
People with IBD and coexisting primary sclerosing cholangitis (PSC) may get faecal calprotectin tests to monitor colon inflammation. If PSC raises FC independently of colitis, FC could mislead decisions about IBD...
NUDT15 variants strongly affect how people metabolize thiopurine drugs used in IBD; knowing variant frequency helps decide whether routine pre-treatment genotyping is useful in Iran and among specific ethnic groups.
